Alpine Immune Sciences (ALPN) Announces $100M Proposed Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Alpine Immune Sciences Announces Proposed Public Offering
September 20, 2022 4:15 PM EDTSEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock and, in lieu of shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to... More
